ICB therapy is an emerging immunotherapy aiming at blocking immunosuppressive tumor signals and restoring anti-tumor immune responses by targeting checkpoint receptors or ligands such as PD-1/PD-L1, CTLA-4, TIGIT, LAG-3, TIM3, among which PD-1/PD-L1 is the most common research object. This evidence concerns the gene CD274 and neoplasm.